IP Library Granted Patent US 10,159,702
Granted Patent B2
US 10,159,702 · App. 15/841,830 · Granted Dec 25, 2018

Synergistic combinations of caffeine, ginkgo biloba and beta-phenylethylamine

Inventors: Itschak Lamensdorf (Modi'in, IL); Yoram Sela (Ra'anana, IL); Mor Zeilkha (Ramat Gan, IL)
Assignee: TRINUTRA LTD.
A61K36/16A61K9/2009A61K9/2054A61K31/137A61K31/522A61K36/258A61K36/484A61K36/77A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,159,702
App. No.
15/841,830
Granted
Dec 25, 2018
Kind
B2
Abstract

The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, ginkgo biloba , and β-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

Claims (19)

1. A composition comprising a therapeutically effective amount of caffeine, ginkgo biloba , and β-phenylethylamine (PEA) or its salt, wherein a weight ratio between the caffeine, ginkgo biloba , and PEA or its salt is in the range of 1 caffeine: 0.1-6 ginkgo biloba: 1.6-12.5 PEA, and wherein the therapeutically effective amount is a synergistic amount effective to treat a behavioral and/or neurodevelopmental disorder.

2. The composition according to claim 1 , further comprising actives selected from the group consisting of guarana, ginseng , kaempferol, curcumin, licorice, Amur Corktree ( Phellodendron amurense ), licorice root ( Glycyrrhiza glabra and Glycyrrhiza uralensis ), Psoralea Fruit ( Psoralea corylifolia ) and Bakuchi seed ( Cyamposis psoralioides ) and combinations thereof.

3. The composition according to claim 1 , wherein the weight ratio between the caffeine, ginkgo biloba , and PEA or its salt is in the range of 1 caffeine:2.6 ginkgo biloba: 1.6-5 PEA.

4. The composition according to claim 1 , wherein the weight ratio between the caffeine, ginkgo biloba , and PEA or its salt is 1 caffeine:6 ginkgo biloba: 3 PEA.

5. The composition of claim 1 , wherein said composition is formulated in the form of tablets, caplets, capsules, powders, sachets for suspension or dispersible tablets to be added to water.

6. An oral dosage form comprising a composition according to claim 1 .

7. The oral dosage form according to claim 6 , wherein the amount of caffeine is in the range of 30-200 mg per unit dose.

8. The oral dosage form according to claim 7 , comprising 40-100 mg caffeine, 100-400 mg ginkgo biloba and 100-200 mg PEA per unit dose.

9. The oral dosage form according to claim 7 , comprising 50 mg caffeine, 300 mg ginkgo biloba and 150 mg PEA per unit dose.

10. The oral dosage form according to claim 6 , comprising 30-200 mg caffeine, 50-500 mg ginkgo biloba and 50-1000 mg PEA per unit dose.

11. The oral dosage form according to claim 6 , further comprising one or more pharmaceutical excipients.

12. The oral dosage form according to claim 6 , wherein all of the active components are formulated for immediate release.

13. The oral dosage form according to claim 6 , wherein at least a portion of the ginkgo biloba is formulated for controlled release.

14. A method of treating a psychological, psychiatric, behavioral and/or neurodevelopmental disorder in a patient comprising administering a therapeutically effective amount of a synergistic combination of caffeine, ginkgo biloba , and PEA or its salt in the weight ratios of 1 caffeine; 0.1-6 ginkgo biloba; 1.6-12.5 PEA to the patient in need thereof.

15. The method of treatment of claim 14 wherein the patient is a child.

16. The method of treatment of claim 14 wherein the patient is an adult.

17. The method of treatment of claim 14 , wherein the psychological, psychiatric, behavioral and/or neurodevelopmental disorder is selected from the group comprising ADHD, depression, autism, mood disorders in general, posttraumatic stress disorder, Alzheimer's disease and Parkinson's disease.

18. The method of treatment of claim 14 , wherein the disorder is ADHD.

19. The method of treatment of claim 14 , wherein the composition is administered in amount such that the daily dosage of each active component is in the range of 10-200 mg caffeine, 20-1000 mg ginkgo biloba and 30-600 mg PEA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2019
From: LAMENSDORF, ITSCHAK; SELA, YORAM; ZEILKHA, MOR
To: TRINUTRA LTD.
Reel/Frame 049559/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2018
From: LAMENSDORF, ITSCHAK; SELA, YORAM; ZEILKHA, MOR
To: TRINUTRA LTD.
Reel/Frame 046031/0920 →
Continuity (3)
Continuation PCTIL2017050733 · Jun 29, 2017
Provisional Application 62367792 · Jul 28, 2016
Related Publication 20180104292A1 · Apr 19, 2018